Developing Innovative High-Impact Therapeutic Solutions that Address Major Unmet Needs in Healthcare

Learn More

Orchestra BioMed is a Healthcare Innovation Company

Orchestra BioMed is a biomedical innovation company focused on developing high-impact therapeutic solutions to address significant unmet needs in cardiovascular health and other areas. We specialize in developing novel therapies that are:

  • Designed to fit current clinical treatment paradigms and leverage the established procedural techniques well-known to interventional physicians; and
  • Based on the use as well as convergence of advanced medical technology, biopharmaceuticals, biomaterials-based drug delivery, and intelligent bioelectronic therapeutic algorithms

Our business model is designed to advance promising therapeutic solutions through development and aims to leverage strategic partnerships with established global commercial leaders to optimize commercialization and profitability. The Orchestra BioMed team of industry leaders has proven expertise in every phase of medtech and biopharma product development. Our primary focus on cardiovascular disease reflects our goal to rapidly advance disruptive solutions that will improve the standard of care for millions of patients worldwide.

Product Pipeline Overview

Advancing a deep, multi-asset pipeline of high-impact therapeutic solutions built around two technology platforms.

Learn More

News & Events

Orchestra BioMed™ Completes $34 Million Financing to Accelerate Product Pipeline Development and Advance Partnerships

July 10, 2019

  • Series B-1 Round Led by Perceptive, RTW and Soleus Capital with Strategic Participation from Terumo Corporation
  • Secures $64 Million in 2019 Capital Inflows, Including $30 Million Upfront Payment from Terumo Partnership
  • Financing Structure Provides Up to an Additional $57 Million in Follow-On Investments from Existing Shareholders

Orchestra BioMed™ Announces Global Strategic Partnership with Terumo Corporation for Development and Commercialization of Virtue® Sirolimus-Eluting Balloon

June 13, 2019

  • Virtue® SEB is expected to become a flagship therapeutic product for Terumo and will strengthen its broad US and global portfolio of interventional solutions
  • Terms of the partnership include substantial up-front and milestone payments, equity investment, a strong commitment to global clinical program, as well as meaningful revenue sharing through royalty and exclusive drug formulation supply payments
  • Partnership validates Orchestra BioMed’s strategy to leverage alliances with established market leaders to drive global commercialization of its high-impact products

Read All News